Research Topics
Species | Roderich E SchwarzSummaryAffiliation: University of Texas Southwestern Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trialRoderich E Schwarz
J Clin Oncol 23:5404-5; author reply 5405. 2005
Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statementRoderich E Schwarz
Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390 8548, USA
HPB (Oxford) 15:106-15. 2013....- Clinical impact of lymphadenectomy extent in resectable esophageal cancerRoderich E Schwarz
Division of Surgical Oncology, UT Southwestern Cancer Center, Dallas, TX 75390, USA
J Gastrointest Surg 11:1384-93; discussion 1393-4. 2007..Although the mechanism remains uncertain, it does not appear to be limited to stage migration. ELND during potentially curative esophagectomy for EC can be supported by the data... - An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancerRoderich E Schwarz
Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390 8548, USA
Surgery 146:241-9. 2009..Combination treatments in addition to gemcitabine have failed to improve outcomes in pancreatic cancer. We tested gemcitabine in combination with the antiendothelial agent endothelial monocyte-activating polypeptide II (EMAP II)... - EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancerRoderich E Schwarz
Department of Surgery, Division of Surgical Oncology, UT Southwestern Medical Center, Dallas, TX, USA
Ann Surg Oncol 17:1442-52. 2010..We tested the hypothesis that a combination of EMAP with bevacizumab (Bev) and gemcitabine (Gem) targets different pathways of PDAC progression and represents more effective treatment... - Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferationRoderich E Schwarz
UT Southwestern Medical Center, Department of Surgery, Division of Surgical Oncology, Dallas, TX, USA
Cancer Biol Ther 9:632-9. 2010..These findings suggest that EMAP II demonstrates significant antitumor activity against PDAC cells, and that this effect may be in part mediated through targeted interference with stromal FN-integrin dependent PDAC cell proliferation... 
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statementRoderich E Schwarz
Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390 8548, USA
HPB (Oxford) 12:313-20. 2010..Patients should undergo formal multidisciplinary evaluation prior to initiating any such treatment in order to individualize the best available options...- Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US populationRoderich E Schwarz
Division of Surgical Oncology, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA
Am J Surg 195:829-36. 2008..Hepatocellular cancer (HCC) frequently presents with limitations to resection. We investigated survival outcomes after various local HCC therapies in US patients... - Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancerNiranjan Awasthi
Division of Surgical Oncology, Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, Texas, USA
PLoS ONE 7:e38477. 2012..Combination of antiangiogenic agents improves gemcitabine response, with sunitinib inducing the strongest effect. These findings demonstrate advantages of combining multi-targeting agents with standard gemcitabine therapy for PDAC... - Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapyNiranjan Awasthi
Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390 8548, USA
Cancer Chemother Pharmacol 68:571-82. 2011..Endothelial monocyte-activating polypeptide II (EMAP) enhances gemcitabine effects in PDAC. We evaluated the combination effects of EMAP, doxorubicin, and docetaxel in experimental PDAC... - Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancerNiranjan Awasthi
Division of Surgical Oncology, Department of Surgery, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 8548, USA
HPB (Oxford) 13:597-604. 2011..Sunitinib (Su) is a novel, multi-target receptor tyrosine kinase inhibitor that has antitumour activities. This study tested the benefits of combined gemcitabine and sunitinib in PDAC... - Androgen receptor blockade in experimental combination therapy of pancreatic cancerSrivani Konduri
Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Divisions of Surgical Oncology and Surgical Sciences, The Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
J Surg Res 142:378-86. 2007..Reports on hormone receptor expression of pancreatic cancer (PaCa) cells and treatment responses to antihormonal therapy are still conflicting... - Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signalingNiranjan Awasthi
Department of Surgery, University of Texas Southwestern Medical Center, UT Southwestern School of Medicine, Dallas, TX 75390 8548, USA
Lab Invest 89:38-46. 2009.... - The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancerNiranjan Awasthi
Division of Surgical Oncology, Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
J Cell Biochem 113:784-91. 2012..These findings demonstrate advantages of combination therapy strategies targeting multiple pathways in pancreatic cancer treatment... - Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancerNiranjan Awasthi
Division of Surgical Oncology, Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, TX, USA
Cancer Biol Ther 10:99-107. 2010..The potential value of proteasome inhibition in experimental therapy approaches for PDAC appears to relate primarily to the combination with the cytotoxic drug rather than with the antiendothelial agent... - Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancerAmanda Kirane
Division of Surgical Oncology, Department of Surgery, The Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Clin Cancer Res 18:5031-42. 2012..Here, we report that apricoxib, a novel COX-2 inhibitor in phase II clinical trials, significantly enhances the efficacy of gemcitabine/erlotinib in preclinical models of pancreatic cancer... - In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-IIRoderich E Schwarz
Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, and The Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA
J Surg Res 120:64-72. 2004..We tested this strategy in an in vivo model of local tumor progression utilizing an agent with previously identified direct antiendothelial properties... - Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancerNiranjan Awasthi
Division of Surgical Oncology, Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
BMC Cancer 11:15. 2011..Smac is an endogenous IAP-antagonist, which renders synthetic Smac mimetics attractive anticancer agents. We evaluated the benefits of combining a Smac mimetic, JP1201 (JP), with conventional chemotherapy agents used for PDAC management... - Factors influencing change of preoperative treatment intent in a gastrointestinal cancer practiceRoderich E Schwarz
Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Division of Surgical Oncology, The Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA
World J Surg Oncol 5:32. 2007..Postoperative assessment of indications for cancer directed surgical procedures frequently differs from preoperative plans... - Lymph node dissection impact on staging and survival of extrahepatic cholangiocarcinomas, based on U.S. population dataRoderich E Schwarz
Division of Surgical Oncology, The Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA
J Gastrointest Surg 11:158-65. 2007..Although the resulting incremental benefit is small, dissection and examination of 10 or more LNs should be considered for curative intent resections... - Estrogen receptor beta/alpha ratio predicts response of pancreatic cancer cells to estrogens and phytoestrogensSrivani Konduri
Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Division of Surgical Oncology, The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA
J Surg Res 140:55-66. 2007..We examined estrogen receptor (ER) expression in PaCa cells and investigated its function in estrogen-mediated cell proliferation... - Endothelial-monocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta1 integrinMargaret A Schwarz
Department of Surgery, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 125 Paterson Street, CAB 7319, New Brunswick, NJ 08903, USA
Exp Cell Res 311:229-39. 2005.... - Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population databaseRoderich E Schwarz
Division of Surgical Oncology, The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, New Jersey 08903, USA
Ann Surg Oncol 13:1189-200. 2006..Operative therapy of pancreatic cancer is associated with poor survival because of high recurrence rates after pancreatectomy. The effect of lymph node (LN) dissection on survival continues to be debated... - Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infectionAdam C Yopp
Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
Clin Gastroenterol Hepatol 10:1284-90. 2012..We compared the clinical presentation, treatment, and survival of patients with HCC, with and without HIV infection... - Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancreatic cancerJohn H Heinzerling
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA
Radiat Oncol 6:146. 2011.... - Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypesChristina L Roland
Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390 9155, USA
J Surg Oncol 105:595-600. 2012..This study examined the survival impact of malignant pancreatic ICT morphologic subtypes... - Routine nasogastric decompression is unnecessary after pancreatic resectionsChristina L Roland
Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9155, USA
Arch Surg 147:287-9. 2012..001). Our experience demonstrates that the use of NGTs can be safely avoided in patients who are undergoing pancreatectomies... - Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP IINiranjan Awasthi
Division of Surgical Oncology, Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
J Exp Clin Cancer Res 32:12. 2013..Endothelial monocyte activating polypeptide II (EMAP) enhances gemcitabine effects in PDAC. Antitumor activity of sorafenib was evaluated in combination with gemcitabine (Gem) and the antiangiogenic agent EMAP in experimental PDAC... - BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancerNiranjan Awasthi
Division of Surgical Oncology, Simmons Comprehensive Cancer Center, The University of Texas Southern Medical Center, Dallas, TX 75390, USA
Mol Cancer Ther 11:2644-53. 2012..05), and in the BMS-754807+gemcitabine combination group, 41 days (P = 0.007). The strong antitumor activity of BMS-754807 in experimental PDAC supports the potential of BMS-754807-induced mechanisms for clinical PDAC therapy... - Rare hepatic arterial anatomic variants in patients requiring pancreatoduodenectomy and review of the literatureSmita Ramanadham
Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390 9155, USA
Case Rep Surg 2012:953195. 2012..0%. In the present paper, we describe the hepatic arterial anomalies commonly encountered and clarify the important details associated with these variants as they pertain to pancreatoduodenectomy... - Pathologic response to preoperative therapy: does it mean what we think it means?John C Mansour
Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center at Dallas, USA
Ann Surg Oncol 16:1465-79. 2009..In addition, we address some alternative strategies to gauge the response of a tumor to preoperative therapy... - Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancerChanghua Zhang
Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas Hamon Center for Therapeutic Oncology Research, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas Department of Gastrointestinopancreatic Surgery, the First Affiliated Hospital of Sun Yat Sen University, Guangzhou, Guangdong, China
J Surg Res 182:227-34. 2013..The present study was performed to test peritoneal dissemination gastric cancer xenografts mouse models that would support survival outcome analyses... - Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancerChanghua Zhang
Division of Surgical Oncology, Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, Texas, United States of America
PLoS ONE 8:e58037. 2013..Nab-paclitaxel benefits were observed independent from phosphorylated stathmin expression at baseline, putting into question the consideration of nab-paclitaxel use in gastric cancer based on this putative biomarker... - Intraduodenal sarcoma recurrence of retroperitoneal origin: an unusual cause for a duodenal obstructionJean J Bao
Department of Surgery, Division of Surgical Oncology, UT Southwestern Medical Center, Dallas, TX, USA
World J Surg Oncol 10:59. 2012..This unusual recurrence pattern likely relates to the patient's previous resection and radiation treatment, and highlights the benefits, limitations and follow-up strategies after multimodality treatment... - Extended left-sided pancreatectomy with spleen preservationArash Mohebati
Division of Surgical Oncology, Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, New Brunswick, NJ, USA
J Surg Oncol 97:150-5. 2008..Distal pancreatectomy (DP) is frequently performed with splenectomy, although splenectomy can be linked to various untoward effects, and sparing of the main splenic vessels (SVs) is not necessary for successful spleen preservation (SP)... - Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastasesWilliam Rule
Department of Radiation Oncology, University of Texas Southwestern, 5801 Forest Park Road, Dallas, TX, USA
Ann Surg Oncol 18:1081-7. 2011..To identify a tolerable and effective dose for 5-fraction stereotactic body radiotherapy for hepatic metastases... - Molecular mechanisms for individualized cancer careJohn C Mansour
Department of Surgical Oncology, University of Texas Southwestern Medical Center at Dallas, Harold C Simmons Cancer Center, Dallas, TX, USA
J Am Coll Surg 207:250-8. 2008 - Factors influencing perioperative blood transfusions in patients with gastrointestinal cancerVarun Verma
Division of Surgical Oncology, The Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
J Surg Res 141:97-104. 2007..Patients undergoing major cancer resections often receive blood transfusions (TFs). Preoperative erythropoietin (EPO) offers the rationale to reduce TFs and related morbidity... - Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCCToshinari Yamasaki
Department of Internal Medicine, Hematology Oncology Division, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Nat Rev Urol 8:165-71. 2011..As the tumor exhibited loss of heterozygosity for FH and markedly reduced FH activity, and in the absence of other established therapies, treatment with the glycolytic inhibitor 2DG (2-deoxy-D-glucose) was explored... - Hypomagnesemia after major abdominal operations in cancer patients: clinical implicationsRoderich E Schwarz
Division of Surgical Oncology, The Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA
Arch Med Res 36:36-41. 2005..Serum magnesium levels are rarely measured in routine chemistry panels. The extent and impact of postoperative serum magnesium changes remain unclear... - Simple feeding jejunostomy technique for postoperative nutrition after major upper gastrointestinal resectionsRoderich E Schwarz
Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
J Surg Oncol 79:126-30. 2002 - Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stageRoderich E Schwarz
Division of Surgical Oncology RES, The Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA
Ann Surg Oncol 14:317-28. 2007..The value of an extended lymph node dissection (ELND) remains unclear in this setting... - Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population databaseDavid D Smith
Division of Biostatistics, City of Hope Cancer Center, Duarte, CA, USA
J Clin Oncol 23:7114-24. 2005.... - Spleen-preserving splenic hilar lymphadenectomy at the time of gastrectomy for cancer: technical feasibility and early resultsRoderich E Schwarz
Department of General Oncologic Surgery, City of Hope National Medical Center, Duarte, California, USA
J Surg Oncol 79:73-6. 2002 - Impact of intraoperative radiation on postoperative and disease-specific outcome after pancreatoduodenectomy for adenocarcinoma: a propensity score analysisRoderich E Schwarz
City of Hope National Medical Center, Department of General Oncologic Surgery, Duarte, California, USA
Am J Clin Oncol 26:16-21. 2003..The recurrence pattern may be affected in some patients, but systemic recurrences predominate. We continue to explore IORT in combination with systemic chemotherapy... - Unusual presentations of uncommon tumors: case 2. Gastric carcinoid metastatic to the liverRoderich E Schwarz
City of Hope National Medical Center, Duarte, CA, USA
J Clin Oncol 20:2403-4. 2002 - Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapyRoderich E Schwarz
Department of General Oncologic Surgery, City of Hope National Medical Center, Duarte, California, USA
Ann Surg Oncol 9:394-400. 2002..Radical gastrectomy with extended lymphadenectomy may reduce LRR, possibly affecting adjuvant treatment strategies... - Gastrectomy circumstances that influence early postoperative outcomeRoderich E Schwarz
City of Hope National Medical Center, Department of General Oncologic Surgery, Duarte, CA, USA
Hepatogastroenterology 49:1742-6. 2002..Despite decreasing mortality, gastric resection is still a procedure of significant morbidity... - Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials?Yasuhiro Kodera
Department of Surgery II, Nagoya University School of Medicine, Nagoya, Japan
J Am Coll Surg 195:855-64. 2002 - Complications of malignancy: case 2. Infectious tissue pneumatosis as a result of colon cancer perforation in a survivor of Hodgkin's diseaseRoderich E Schwarz
Divisions of Surgical Oncology and Medical Oncology, The Cancer Institute of New Jersey, New Burnswick, NJ, USA
J Clin Oncol 22:373-4. 2004 - Pancreatic tumors in patients with lung malignancies: a spectrum of clinicopathologic considerationsRoderich E Schwarz
Department of General Oncologic Surgery, City of Hope National Medical Center, Duarte, CA, USA
South Med J 97:811-5. 2004..To elucidate possible clinical interrelationships, the authors reviewed the clinicopathologic characteristics of patients treated for both pulmonary and pancreatic neoplasms... - Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2Peiguo G Chu
Division of Pathology, City of Hope National Medical Center, Duarte, CA 91010, USA
Am J Surg Pathol 29:359-67. 2005..MUC2+/CDX2+ can be used as positive markers for the intestinal-type adenocarcinoma of duodenal papillary origin with a positive predictive value of 82%... - Quality of life in patients with colorectal metastasis and intrahepatic chemotherapySarah L Blair
University of California at San Diego Department of Surgery, UCSD Cancer Center, La Jolla, California 92093, USA
Ann Surg Oncol 10:144-9. 2003..Hepatic chemotherapy has been used; however, rigorous quality of life (QOL) measurements are lacking. The aim of this study was to describe unique QOL issues to formulate a specific tool for this population...